Concurrent Chemoradiation (Cisplatin-based)

Treatment for Cervical Cancer

Typical Dosage: Cisplatin 40mg/m² weekly for 5-6 cycles, plus EBRT and brachytherapy

Effectiveness
85%
Safety Score
25%
Clinical Trials
67
Participants
50K

Comparative Safety Scale(Higher is safer)

Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
25
DangerousModerateSafe
Treatment Details
Dosage Range
Cisplatin 40mg/m² weekly for 5-6 cycles, plus EBRT and brachytherapy
Time to Effect
During and shortly after treatment
Treatment Duration
5-7 weeks
Evidence Quality
HIGH
Number Needed to Treat (NNT)
6(Treat 6 patients to see 1 additional successful outcome)
Confidence Score
95%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$1,000
Monitoring:$10,000
Side Effect Mgmt:$6,000
Total Annual:$50,000
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOOD
ICER
$60,000/QALY
QALYs Gained
3
Outcome-Based Costs
Cost per Responder
$62,500
Cost per Remission
$76,923
Comparison vs Radiation Therapy alone
Cost Difference
+$15,000/year
More expensive
QALY Difference
+1.00 QALYs
Better outcomes
Dominance
No dominance
Concurrent Chemoradiation (Cisplatin-based) Outcomes

for Cervical Cancer

Efficacy Outcomes
Overall Effectiveness
+85%
Response Rate
+80%
Remission Rate
+65%
Common Side Effects
Fatigue
+85%
Nausea/Vomiting
+75%
Diarrhea/Proctitis
+60%
Cystitis
+40%
Bone marrow suppression
+50%
Peripheral neuropathy
+30%
Sexual dysfunction/Vaginal stenosis
+60%

WARNING: LIMITED TRIALS AVAILABLE

You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!

Active Clinical Trials
10 active trials recruiting for Concurrent Chemoradiation (Cisplatin-based) in Cervical Cancer

Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer

NCT05492123RECRUITINGPHASE2
View Study
112 participants
INTERVENTIONAL
Fortaleza, Brazil +13 more
Started: Aug 30, 2022

Neoadjuvant Ivonescimab Plus Chemotherapy Followed by Concurrent Chemoradiotherapy in High-Risk Locally Advanced Cervical Cancer

NCT07244965NOT YET RECRUITINGPHASE2
View Study
42 participants
INTERVENTIONAL
Hangzhou, China
Started: Dec 1, 2025

Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma

NCT03919552RECRUITINGPHASE3
View Study
482 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 31, 2018

Optimization of Postoperative Adjuvant Therapy for Cervical Cancer Based on MRD(Minimal Residual Disease)

NCT05872724RECRUITINGPHASE2
View Study
32 participants
INTERVENTIONAL
Suzhou, China
Started: Jan 16, 2023

Modulation Therapy for Locally Advanced NPC Based on Plasma EBV DNA Level Post-ICT

NCT05628922RECRUITINGPHASE2
View Study
198 participants
INTERVENTIONAL
Shanghai, China
Started: Jul 2, 2022

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

NCT06288373RECRUITINGPHASE2, PHASE3
View Study
440 participants
INTERVENTIONAL
Hefei, China +11 more
Started: Apr 22, 2024

PD-1 Inhibitor Therapy Versus Radiotherapy in pCR Patients With Locally Advanced HNSCC After Neoadjuvant Immunochemotherapy

NCT05980715RECRUITINGPHASE3
View Study
324 participants
INTERVENTIONAL
Guangzhou, China
Started: Jan 1, 2023

Stereotactic Boost and Short-course Radiation Therapy for Oropharynx Cancer

NCT04178174RECRUITINGPHASE3
View Study
360 participants
INTERVENTIONAL
London, Canada +1 more
Started: Feb 23, 2020

Image Guided IMRT, Radiochemotherapy and MRI-based IGABT in Locally Advanced Cervical Cancer

NCT03617133RECRUITINGPHASE2
View Study
1K participants
INTERVENTIONAL
Vienna, Austria
Started: Apr 1, 2016

Individualized Radiation Dose Prescription in HNSCC Based on F-MISO-PET Hypoxia-Imaging

NCT03865277NOT YET RECRUITINGPHASE2
View Study
276 participants
INTERVENTIONAL
Freiburg im Breisgau, Germany +7 more
Started: Jul 1, 2024
Completed Clinical Trials
5 completed trials for Concurrent Chemoradiation (Cisplatin-based) in Cervical Cancer

Induction Chemotherapy for Advanced Head and Neck Cancer

NCT00959387COMPLETEDPHASE2
View Study
60 participants
INTERVENTIONAL
Barretos, Brazil
Started: Aug 1, 2009

Study Of Adjuvant Lapatinib In High-Risk Head And Neck Cancer Subjects After Surgery

NCT00424255COMPLETEDPHASE3
View Study
688 participants
INTERVENTIONAL
Springfield, United States +116 more
Started: Dec 1, 2006

An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.

NCT03998696COMPLETEDPHASE4
View Study
60 participants
INTERVENTIONAL
Dhaka, Bangladesh
Started: Jul 1, 2017

Platinum-based Chemoradiotherapy and Rigosertib in Head and Neck Cancer

NCT02107235COMPLETEDPHASE1
View Study
2 participants
INTERVENTIONAL
Aurora, United States +3 more
Started: Jan 1, 2014

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

NCT03830866COMPLETEDPHASE3
View Study
770 participants
INTERVENTIONAL
Phoenix, United States +116 more
Started: Feb 15, 2019
Showing 20 of 71 total trials